← Back to Clinical Trials
Recruiting NCT06459388

NCT06459388 Stabilizing Reversal and Rhythmic Stabilization vs Pelvic Proprioceptive Neuromuscular Facilitation in Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06459388
Status Recruiting
Phase
Sponsor Riphah International University
Condition Stroke, Ischemic
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-05-01
Primary Completion 2025-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Stabilizing Reversals and Rhythmic StabilizationPelvic Proprioceptive Neuromuscular Facilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-05-01 with a primary completion date of 2025-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare the effects of stabilizing reversal and rhythmic stabilization versus pelvic proprioceptive neuromuscular facilitation on trunk control, postural stability and mobility in stroke patients. The main question it aims to answer is: Is there any difference in effects of stabilizing reversal and rhythmic stabilization versus pelvic proprioceptive neuromuscular facilitation on trunk control, postural stability and mobility in stroke patients? Researchers will compare stabilizing reversal and rhythmic stabilization to pelvic proprioceptive neuromuscular facilitation to see if there any difference in effects of stabilizing reversal and rhythmic stabilization versus pelvic proprioceptive neuromuscular facilitation on trunk control, postural stability and mobility in stroke patient. Participants will be divided into two groups: Group A will receive stabilizing reversals and rhythmic reversals technique. The patient will perform 3 sets with 15 repetitions in each session, 5 days per week for 8 weeks. Group B will receive Pelvic PNF protocol. The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.

Eligibility Criteria

Inclusion Criteria: * Diagnosed cases of ischemic stroke. * Both genders of stroke patients. * Age of stroke patients between 40-65 years. * Duration of stroke less than 6 months. * Participants should be able to understand and follow simple verbal commands (MMSE * 24). Exclusion Criteria: * Recurrent history of stroke. * Recent history of any trauma. * Musculoskeletal disorders such as low back pain, arthritis, degenerative diseases of the lower limbs affecting motor performance, spinal deformity and contractures. * Spasticity (modified Ashworth scale grade ≥3) or flaccidity in lower limbs and upper limbs. * PNF treatment given to the pelvic region within 6 weeks.

Contact & Investigator

Central Contact

Imran Amjad, Phd

✉ imran.amjad@riphah.edu.pk

📞 03324390125

Principal Investigator

Wajiha Shahid, Phd*

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT06459388 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 65 Years, studying Stroke, Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06459388 currently recruiting?

Yes, NCT06459388 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT06459388 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT06459388 clinical trial?

NCT06459388 is sponsored by Riphah International University. The principal investigator is Wajiha Shahid, Phd* at Riphah International University. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology